TherapeuticsMD (TXMD) Misses Q1 EPS by 2c

TherapeuticsMD (NYSE: TXMD) reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.93 million versus the consensus estimate of $5.73 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance